Dr. Samuel O. OLA

Personal statement / Research focus

Although I became an alumnus of the College of Medicine, UI, Ibadan in I982, I was introduced to research as an apprentice (Medical student) to Dr EA Ayoola collecting data from the case notes of patients with Primary HepatoCellular Carcinoma (PHCC) in 1979 and later vene-puncturing newly delivered pregnant women at Igbo-Ora, Oyo state in 1987 for sero- assay of aflatoxin carried out by Dr IO Olubuyide.

 My research work focused on hepatic diseases and the associated viral infections. Right from outset, it was clinico-laboratory based, with inter and multidisciplinary participation, commenced with identification of sensitive methods for early diagnosis of PHCC such as demonstration of high level of plasma oestradiol, sex hormone binding globulin and abnormal cortisol homeostasis as paraneoplastic features, determination of diagnostic serum levels of tumour markers comprising alpha-feotoprotein (AFP), ferritin and alkaline phosphatase as well as the roles of cutaneous features and routine ultrasonographic assessment of liver for PHCC and thus its early therapy in Nigerians.

Misdiagnosis of PHCC was reduced by defining Amoebic liver abscess as its common differential while HBV more than HCV was demonstrated to be etiologically related to PHCC in Nigerians with exposure to blood as a major route for their transmission.

 Hence, further works focused on determination the burden of HBV and HCV infections among different groups of healthy Nigerians and patients through definition of the values of diagnostic methods and their pitfalls, isolation of HBV genotypes by phylogenetic analysis, clinico-serological patterns, HBV infectivity, high risk groups, occult and co-infections with HIV and STD, prescreening for HBV and HIV infection prior administration of vaccination against HBV and therapy of HBV patients using antiviral agents.

My work on HIV infection involved definition of its demography and clinical patterns depending on viral subtypes of among Nigerians and showed the presence of treatment naïve Nigerian patients with HIV-I drug resistant mutations, pioneered HAART therapy at UCH, Ibadan and advocated the need for holistic care of the HIV infected Nigerian patients.

Efforts at diminishing the co-morbidities in Nigerians with liver diseases led to definition of the contributory role of Helicobacter pylori (H. pylori) in causing associated Acid Peptic Disease (APD) and demonstration of the specific site for diagnosis of the bacterium through upper GIT endoscopy as well as the usefulness of a locally manufactured antacid in the therapy of Nigerians with APD.

These researches were possible with grants from the UI, Ibadan and support from UCH, Ibadan; drug companies such as Roche Nigeria Limited, Pharma-Kinetic Limited and GlaxoSmithKline Pharmaceutical Nigeria PLC and overseas affiliation with Adult AIDS Clinical Trial Unit, Northwestern University, Chicago, USA, Manchester Royal Infirmary including Trafford General Hospital, Manchester; UK and Royal Liverpool & Broadgreen University Hospital, Liverpool, UK.

I have been involved with training of undergraduate and post-graduate medical personnel including other healthcare workers since 1985 as well as supervision of fellowship dissertations from 1995. Similarly, I have been offering clinical services to patients since 1982 at UCH, Ibadan and other teaching hospitals in Nigeria and overseas.

Ongoing researches are focused on hepato-trophic viruses, HIV infection, acute and chronic liver andintestinal diseases including those of autoimmune aetiology among Nigerians, the contributory role of GI endoscopy especially ERCP in managing Nigerians with hepato-biliary tree disorders.


Curriculum Vitae